Reports that the U.S.-based National Institutes of Health's Recombinant Advisory Committee (RAC) is trying to regain control over reviewing of all gene therapy clinical trials in the nation, as of September 2001. Views of the researcher regarding the revival; Criticism of the public availability of the information filed with RAC.